---
title: "A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab"
nct_id: NCT07263477
overall_status: COMPLETED
sponsor: Second Affiliated Hospital of Wenzhou Medical University
study_type: OBSERVATIONAL
primary_condition: Crohn Disease (CD)
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07263477.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07263477"
ct_last_update_post_date: 2025-12-04
last_seen_at: "2026-05-12T07:14:21.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab

**NCT ID:** [NCT07263477](https://clinicaltrials.gov/study/NCT07263477)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 900
- **Lead Sponsor:** Second Affiliated Hospital of Wenzhou Medical University
- **Conditions:** Crohn Disease (CD)
- **Start Date:** 2020-01-01
- **Completion Date:** 2025-05-01
- **CT.gov Last Update:** 2025-12-04

## Brief Summary

From January 2020 to May 2025, 303 CD patients and 514 normal controls were retrospectively collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Our study aimed to explore the the relationship of interleukin-7 receptor (IL-7R) gene polymorphisms with the risk of Crohn's disease (CD) onset, the clinicopathological features of CD and the efficacy of infliximab (IFX) therapy.

## Detailed Description

From January 2020 to May 2025, 303 CD patients and 514 normal controls were retrospectively collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Our study aimed to explore the the relationship of interleukin-7 receptor (IL-7R) gene polymorphisms with the risk of Crohn's disease (CD) onset, the clinicopathological features of CD and the efficacy of infliximab (IFX) therapy. Multiple polymerase chain reaction ligase detection technology was used to detect the genotype of IL-7R (rs6897932, rs1494555, rs1494558). According to the Montreal CD classification criteria, patients were divided into different subgroups. The Crohn's Disease Activity Index (CDAI) is used to evaluate clinical activity, while the Simplified Crohn's Disease Endoscopic Score (SES-CD) is used to assess endoscopic activity.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* diagnosed CD based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results

Exclusion Criteria:

* rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc.
```

## Arms

- **CD patients** — Some CD patients received intravenous injection of IFX (5mg/kg) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of IFX every 8 weeks to maintain treatment.
- **normal control** — no biological agents treatment

## Interventions

- **Infliximab** (BIOLOGICAL) — Intravenous injection of IFX (5mg/kg) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of IFX every 8 weeks to maintain treatment.

## Primary Outcomes

- **Genotypes of IL-7R** _(time frame: Baseline)_ — multiplex polymerase chain reaction-ligase detection reaction technique

## Locations (1)

- the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the second affiliated hospital of wenzhou medical university|wenzhou|zhejiang|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07263477.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07263477*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*